RecruitingN/ADMT

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

Sponsored by University of Rochester

NCT ID
NCT06941389
Target Enrollment
480 participants
Start Date
2024-06-01
Est. Completion
2030-10-01

About This Study

The WeDecide study is a large observational study comparing the long-term effects of matched related donor hematopoietic stem cell transplantation (MRD HCT) and non-transplant disease-modifying therapies (NT-DMT) for pediatric patients with sickle cell disease (SCD). The study aims to assess health-related quality of life (HRQoL), cognitive function, risks, and benefits of both treatments, including survival rates, chronic complications, and organ damage prevention. With 160 children in the MRD HCT group and 320 in the NT-DMT group, aged 3-20.9 years, the study will follow participants for three years, examining factors like disease severity, treatment history, and social determinants of health. By providing a comprehensive comparison, the study seeks to inform clinical decisions and improve understanding of SCD treatment outcomes, ultimately supporting families and healthcare providers in choosing the best treatment options.

Conditions Studied

Sickle Cell Disease (SCD)

Eligibility

Age:3 Years - 20 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Pediatric patients aged between 3 and 20.9 years.
* Children diagnosed with sickle cell Anemia (HB SS or HBSB0 Thalassemia)
* For the MRD HCT group, children who are candidates for matched related donor hematopoietic stem cell transplantation (MRD HCT).
* For the NT-DMT group, children who are receiving non-transplant disease-modifying therapies (NT-DMT) for SCD.
* Participants (or their guardians) must provide informed consent to be part of the study.
* Participants must be willing to undergo the necessary assessments and follow-up visits over the 3-year study period.

Exclusion Criteria:

* Children younger than 3 years or older than 20.9 years.
* Children who do not have sickle cell anemia or related conditions.
* For the MRD HCT group, children who are not eligible for the transplant or do not have a matched related donor.
* Children who are currently enrolled in other clinical trials that might interfere with the WeDecide study.
* Children who are unable to adhere to the study protocol or follow-up requirements.

Study Locations (37)

Children's of Alabama (MRD-HCT)
Birmingham, Alabama, United States
Children's of Alabama (NT-DMT)
Birmingham, Alabama, United States
Nemours Children's Hospital, Delaware (MRD-HCT)
Wilmington, Delaware, United States
Children's National Hospital (MRD-HCT)
Washington D.C., District of Columbia, United States
Children's Healthcare of Atlanta (MRD-HCT)
Atlanta, Georgia, United States
Comer Children's Hospital (MRD-HCT)
Chicago, Illinois, United States
Riley Children's Hospital (MRD-HCT)
Indianapolis, Indiana, United States
Riley's Children Hospital (NT-DMT)
Indianapolis, Indiana, United States
Boston Children's Hospital (MRD-HCT)
Boston, Massachusetts, United States
Boston Children's Hospital (NT-DMT)
Boston, Massachusetts, United States

+27 more locations

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease | Huxley